Table of Contents
- Clinical trial overview
- Who can join the study
- What the trial is measuring
- Study design and phase
- Trial status and size
Clinical trial overview
The available trial is a Phase 3 study in RET-mutant medullary thyroid cancer.[1] It compares selpercatinib with cabozantinib or VANDETANIB in patients with progressive, advanced disease.[1]
The study is interventional, which means people in the trial receive a treatment so researchers can compare results between groups.[1] The trial is authorised and includes 273 participants.[1]
Who can join the study
This trial is for patients with progressive, advanced, kinase inhibitor naïve, RET-mutant medullary thyroid cancer.[1] “Kinase inhibitor naïve” means the patient has not had this type of cancer medicine before.[1]
The study population is therefore a specific group of thyroid cancer patients with a RET gene change and disease that is already advanced or getting worse.[1]
What the trial is measuring
The main outcome is progression-free survival (PFS) by BICR.[1] PFS means the time patients live without their cancer getting worse.[1]
BICR means blinded independent central review, so independent experts review the results without knowing which treatment each patient received.[1] This helps make the comparison between treatments more objective.[1]
Study design and phase
The study title shows that VANDETANIB is part of a comparison against selpercatinib and cabozantinib.[1] This type of design helps researchers see which treatment may work better in this cancer group.[1]
Because it is a Phase 3 trial, it is a later-stage study meant to test treatment benefit in a larger group of patients.[1]
Trial status and size
The trial status is Authorised.[1] The planned enrollment is 273 patients.[1]
Only one trial record was provided, so this article focuses on that study and its main goal: comparing treatment outcomes in RET-mutant medullary thyroid cancer.[1]
